We are monitoring the impact of COVID-19 on North America Autoimmune Monoclonal Antibodies Market Get in touch with us for detailed analysis Know More
Share on

North America Autoimmune Monoclonal Antibodies Market Research Report – Segmented By Source, Application, End User & Country (United States, Canada & Rest of North America) – Industry Size, Share, Trends, Growth & Forecasts (2022 to 2027)

Published: January, 2022
ID: 1106
Pages: 145

North America Autoimmune Monoclonal Antibodies Market Size  (2022 to 2027)

The size of the North America Autoimmune Monoclonal Antibodies Market is expected to reach USD 14771.27 million by 2027 from USD 9837.16 million in 2022, growing at a CAGR of 8.47% during the forecast period 2022 to 2027. 

The Autoimmune monoclonal antibodies market in North America is expected to be driven by the increasing prevalence of autoimmune disorders. Also, the rising prevalence of chronic diseases such as cancer is projected to propel market growth. In addition, other factors such as the Y-O-Y growing population and associated lifestyles disorders further contribute to the market growth. Also, the increasing severe arthritis and multiple sclerosis cases significantly increased demand for the autoimmune monoclonal antibodies market during the forecast period. 

In addition, technological advancements and innovative genetic platforms, including next-generation sequencing, are most likely to boost the market growth.  The increasing number of research and development activities is projected to offer significant growth opportunities to the market growth. Over the years, the market gained its momentum owing to the increased family history of immune diseases. Growing investments and funding by the government for infrastructure development and research and development activities are expected to boost the market growth. 

The strategies by the key market participants such as collaborations, mergers, and acquisitions help the regional market expansion and gain competitively advanced over the market players in the region.  

However, the stringent government regulations are majorly hindering market growth. In addition, the limited access to monoclonal antibody therapeutics owing to its high cost impedes market growth. 

This research report on the North America autoimmune monoclonal antibodies market has been segmented and sub-segmented into the following categories

By Source:

  • Murine
  • Chimeric
  • Humanized
  • Human

By Application:

  • Systemic Lupus Erythematosus
  • Rheumatoid Arthritis
  • Multiple Sclerosis
  • Transplant Rejection/Graft Versus Host Disease

By End-User: 

  • Hospitals/Clinics
  • Research Institutes
  • Diagnostic Laboratories

By Country:

  • United States
  • Canada
  • Rest of North America

Geographically, the North American regional market held the majority share of the global Autoimmune monoclonal antibodies market in 2020, and it is anticipated to register a significant share during the forecast period. Increasing federal support for the treatment of the cancer population, availability of advanced healthcare infrastructure, and favorable government policies are driving the market growth. Also, the market has benefited from an increased emphasis on genomics research and innovation and the introduction of technologically novel genetic platforms such as next-generation sequencing. Emerging countries such as U.S. and Canada are expanding the regional market growth with a significant market share.

The United States recorded the largest share in North America in 2020. The increasing number of product approvals, availability of pharmaceutical companies, and high research and development activities are fuelling the market growth. In addition, the rising prevalence of autoimmune disorders, growing awareness, and increased healthcare spending is fuelling the market growth.

The Canadian market is projected to grow considerably during the forecast period. Supportive government policies, advancement, and the advent of the innovative genetic platform, surging R&D activities are boosting the market growth. 

KEY MARKET PLAYERS:

Companies playing a dominating role in the North American Autoimmune Monoclonal Antibodies market include GlaxoSmithKline plc (U.K.), AstraZeneca plc (U.K.), F. Hoffmann-La Roche Ltd. (Switzerland), Bristol-Myers Squibb (U.S.), Johnson & Johnson (U.S.), Innovent Biologics, Inc. (China), Takeda Pharmaceutical Company Ltd. (Japan), Amgen Inc. (U.S.), Biogen Inc.(U.S.), and UCB Company (Belgium).

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 By Source                    

                                5.1.1 Murine     

                                5.1.2 Chimeric  

                                5.1.3 Humanized             

                                5.1.4 Human     

                5.2 By Application                           

                                5.2.1 Systemic Lupus Erythematosus      

                                5.2.2 Rheumatoid Arthritis          

                                5.2.3 Multiple Sclerosis 

                                5.2.4 Transplant Rejection/Graft Versus Host Disease     

                                5.2.5 Others      

                5.3 End User                     

                                5.3.1 Hospitals/Clinics   

                                5.3.2 Research Institute

                                5.3.3 Diagnostic Laboratories     

6. Geographical Analysis                                              

                6.1 North America                          

                                6.1.1 Introduction           

                                6.1.2 United States         

                                6.1.3 Canada     

7. Pipeline Product Analysis                                        

                7.1 Overview                    

                7.2 Pipeline Development Landscape                     

                7.3 Molecular Targets in the Pipeline                      

                7.4 Clinical Trials                              

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target       

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target               

                7.5 Key Trends in Monoclonal Antibodies Development                 

                                7.5.1 Targeted Therapies             

                7.6 Promising Monoclonal Antibodies in Pipeline                              

                7.7 Heat Map of Safety and Efficacy for Pipeline and Marketed Monoclonal Antibodies                   

8.Strategic Analysis                                        

                8.1 PESTLE analysis                         

                                8.1.1 Political     

                                8.1.2 Economic 

                                8.1.3 Social         

                                8.1.4 Technological         

                                8.1.5 Legal          

                                8.1.6 Environmental      

                8.2 Porter’s Five analysis                              

                                8.2.1 Bargaining Power of Suppliers        

                                8.2.2 Bargaining Power of Consumers    

                                8.2.3 Threat of New Entrants     

                                8.2.4 Threat of Substitute Products and Services

                                8.2.5 Competitive Rivalry within the Industry      

9.Market Leaders' Analysis                                          

                9.1 GlaxoSmithKline plc (U.K.)                   

                                9.1.1 Overview

                                9.1.2 Product Analysis   

                                9.1.3 Financial analysis  

                                9.1.4 Recent Developments       

                                9.1.5 SWOT analysis       

                                9.1.6 Analyst View          

                9.2 AstraZeneca plc (U.K.)                           

                9.3 F. Hoffmann-La Roche Ltd. (Switzerland)                       

                9.4 Bristol-Myers Squibb (U.S.)                 

                9.5 Johnson & Johnson (U.S.)                    

                9.6 Innovent Biologics, Inc. (China)                          

                9.7 Takeda Pharmaceutical Company Ltd. (Japan)                             

                9.8 Amgen Inc. (U.S.)                     

                9.6 Innovent Biologics, Inc. (China)                          

                9.10 UCB Company (Belgium)                    

10.Competitive Landscape                                          

                10.1 Market share analysis                          

                10.2 Merger and Acquisition Analysis                     

                10.3 Agreements, collaborations and Joint Ventures                       

                10.4 New Product Launches                       

11.Expert Opinions                                         

                11.1 Market Outlook                     

                11.2 Investment Opportunities                 

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  1. North America Autoimmune Monoclonal Antibodies Market By Region, From 2022 - 2027 (USD Million)
  2. North America Autoimmune Monoclonal Antibodies Market By Source, From 2022 - 2027 (USD Million)
  3. North America Murine Monoclonal Antibodies Market By Region, From 2022 - 2027 (USD Million)
  4. North America Chimeric Monoclonal Antibodies Market By Region, From 2022 - 2027 (USD Million)
  5. North America Humanized Monoclonal Antibodies Market By Region, From 2022 - 2027 (USD Million)
  6. North America Human Monoclonal Antibodies Market By Region, From 2022 - 2027 (USD Million)
  7. North America Autoimmune Monoclonal Antibodies Market By Application, From 2022 - 2027 (USD Million)
  8. North America Systemic Lupus Erythematosus Market By Region, From 2022 - 2027 (USD Million)
  9. North America Rheumatoid Arthritis Market By Region, From 2022 - 2027 (USD Million)
  10. North America Multiple Sclerosis Market By Region, From 2022 - 2027 (USD Million)
  11. North America Transplant Rejection/Graft Versus Host Disease Market By Region, From 2022 - 2027 (USD Million)
  12. North America Other Applications Market By Region, From 2022 - 2027 (USD Million)
  13. North America Autoimmune Monoclonal Antibodies Market By End User, From 2022 - 2027 (USD Million)
  14. North America Hospitals/Clinics Market By Region, From 2022 - 2027 (USD Million)
  15. North America Research Institute Market By Region, From 2022 - 2027 (USD Million)
  16. North America Diagnostic Laboratories Market By Region, From 2022 - 2027 (USD Million)
  17. United States Autoimmune Monoclonal Antibodies Market By Source, From 2022 - 2027 (USD Million)
  18. United States Autoimmune Monoclonal Antibodies Market By Application, From 2022 - 2027 (USD Million)
  19. United States Autoimmune Monoclonal Antibodies Market By End User, From 2022 - 2027 (USD Million)
  20. Canada Autoimmune Monoclonal Antibodies Market By Source, From 2022 - 2027 (USD Million)
  21. Canada Autoimmune Monoclonal Antibodies Market By Application, From 2022 - 2027 (USD Million)
  22. Canada Autoimmune Monoclonal Antibodies Market By End User, From 2022 - 2027 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

excel
$

3335


pdf excel
$

3680


pdf excel powerbi
$

5520


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 3335

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample